TOPBP1 native long peptide

TOPBP1 native long peptide is a synthetic long peptide (SLP) derived from the DNA topoisomerase II binding protein 1 (TOPBP1), a protein involved in DNA replication and damage repair that can serve as a tumor-associated neoantigen. Developed by researchers at Duke University, this peptide was evaluated as a potential cancer vaccine component for the treatment of glioblastoma (GBM). In preclinical studies, the native long peptide was used to assess its ability to induce anti-tumor T-cell responses; however, it was found to be poorly immunogenic on its own, failing to elicit significant interferon-gamma (IFNγ) secretion or tumor growth inhibition in mouse models. This lack of efficacy led to the exploration of conjoined peptide strategies, such as Topbp1MHCI-P30, where the TOPBP1 neoepitope is linked to a universal helper epitope to enhance its therapeutic potential.

Other names

native long Topbp1 peptideTopbp1 long peptideTopbp-1 long peptideTopbp 1 long peptide